Brief: AB Science Gets First Authorisations For Phase 3 In AD Study

AB Science SA

10/10/2022 17:09

Oct 10 (Reuters) - AB SCIENCE SA  ABS.PA :
    * AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO
INITIATE
CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE
TREATMENT OF ALZHEIMER'S DISEASE
    * STUDY WILL ENROLL 600 PATIENTS WITH CONFIRMED CLINICAL
DIAGNOSIS
OF MILD AND MODERATE ALZHEIMER'S DISEASE
    * PRIMARY ENDPOINT OF STUDY WILL BE TO EVALUATE EFFECT OF
MASITINIB ON ABSOLUTE CHANGE FROM BASELINE IN ADCS-ADL SCORE AND
IN ADAS-COG-11
    * THE OBJECTIVE OF STUDY AB21004 IS TO CONFIRM TREATMENT
EFFECT
WITH MASITINIB 4.5 MG/KG/DAY AS AN ADJUNCT TO CHOLINESTERASE
INHIBITOR AND/OR MEMANTINE IN PATIENTS WITH MILD-TO-MODERATE
ALZHEIMER'S DISEASE

Source text for Eikon:  ID:nGNX8kT3ZP 
Further company coverage:  ABS.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))